ArticleEuropean heart journal. Cardiovascular pharmacotherapy2018

Modelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting.

Max Korman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.